ibrutinib

Conference Coverage

Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL

12/12/2022

Craig Ostroff

At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.

At the 64th ASH Annual Meeting...

12/12/2022

Journal of Clinical Pathways

Conference Coverage

Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL

12/09/2020

Journal of Clinical Pathways

Research in Review

New Biomarker for Relapsed or Refractory MZL Identified

02/27/2017

JCP Editors

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

...

02/27/2017

Journal of Clinical Pathways